aTYR PHARMA INC

Listed Company

ATYRCIK 0001339970NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

$190.0K

Net Income

$-74.12M

Total Assets

$93.00M

Equity

$67.48M

Shares Out

98.05M

Op. Cash Flow

$-61.99M

Business

aTYR PHARMA INC develops novel biotherapeutic drug candidates focused on inflammatory and fibrotic lung diseases and other indications. The company’s main offerings are therapeutic product candidates discovered on its proprietary platform, including efzofitimod, which it advances through preclinical and clinical development. aTYR operates through research and development and collaborative arrangements with third-party contract development and manufacturing organizations and strategic partners. Its programs are primarily pursued through clinical trials and regulatory pathways in the United States and via partnerships for broader development and commercialization.

Summary from filing dated 2025-03-13

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	Trend	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue, Product and Service [Extensible Enumeration]		—	—	—	—	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	11	11	23	10	2
Available-for-sale investments	68	61	76	56	106
Other receivables	873,000	2	2	12	435,000
Prepaid expenses	677,000	8	2	3	5
Total current assets	80	82	103	81	114
Restricted cash	2	3	3	3	0
Property and equipment, net	4	5	6	3	543,000
Operating lease, right-of-use assets	6	6	7	7	1
Financing lease, right-of-use assets	596,000	1	2	1	0
Other assets	148,000	66,000	131,000	193,000	158,000
Total assets	93	97	121	96	116
Accounts payable	4	4	4	3	1
Accrued expenses	10	9	12	10	4
Current portion of operating lease liability	836,000	711,000	831,000	630,000	980,000
Current portion of financing lease liability	630,000	541,000	497,000	264,000	0
Total current liabilities	15	15	16	14	6
Long-term operating lease liability, net of current portion	10	11	12	10	398,000
Long-term financing lease liability, net of current portion	259,000	887,000	1	1	0
Commitments and contingencies (Note 6)	—	—	—	—	—
Preferred stock, $0.001 par value per share; 5,000,000 undesignated authorized shares as of December 31, 2025 and 2024, respectively; no shares issued or outstanding as of December 31, 2025 and 2024, respectively	—	—	—	—	—
Common stock, $0.001 par value per share; 170,000,000 authorized shares as of December 31, 2025 and 2024, respectively; issued and outstanding shares - 98,031,104 as of December 31, 2025 and 84,038,922 as of December 31, 2024, respectively	98,000	84,000	63,000	29,000	28,000
Additional paid-in capital	674	602	559	490	482
Accumulated other comprehensive loss	−8,000	−40,000	−74,000	−433,000	−263,000
Accumulated deficit	−606	−532	−468	−418	−372
Total aTyr Pharma stockholders equity	67	70	91	71	109
Noncontrolling interest in Pangu BioPharma Limited	−192,000	−187,000	−188,000	−180,000	−175,000
Total stockholders' equity	67	70	90	71	109
Total liabilities and stockholders equity	93	97	121	96	116

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	700,000	700,000	600,000	200,000	500,000
Stock-based compensation	5	3	3	2	2
Accretion of discount of available-for-sale investment securities	−2	−3	−3	533,000	366,000
Amortization of right-of-use assets	889,000	832,000	2	1	829,000
Gain on disposal of property and equipment	−12,000	−3,000	−6,000	−92,000	6,000
Other receivables	863,000	402,000	9	−12	2
Prepaid expenses and other assets	7	−6	622,000	2	−3
Accounts payable and accrued expenses	−33,000	−1	3	7	47,000
Operating lease liability	−711,000	−343,000	2	2	−861,000
Net cash used in operating activities	−62	−69	−33	−42	−33
Purchases of property and equipment	−77,000	−65,000	−4	−2	−192,000
Purchases of available-for-sale investment securities	−93	−69	−107	−42	−127
Maturities of available-for-sale investment securities	88	86	91	91	35
Proceeds from sale of property and equipment	12,000	7,000	15,000	179,000	50,000
Net cash (used in) provided by investing activities	−5	17	−20	47	−92
Proceeds from issuance of common stock through option exercises	19,000	0	0	1,000	62,000
Proceeds from issuance of common stock through employee stock purchase plan	108,000	100,000	105,000	44,000	11,000
Proceeds from issuance of common stock from at-the-market offerings, net of offering costs	66	40	18	5	14
Proceeds from issuance of common stock from underwritten follow-on public offering, net of offering costs	0	0	48	0	81
Principal paid on finance lease liabilities	−539,000	−497,000	−394,000	−66,000	0
Net cash provided by financing activities	66	40	66	5	110
Net change in cash, cash equivalents and restricted cash	−1	−12	13	11	−15
Interest paid	94,000	137,000	172,000	54,000	0
Purchases of property and equipment in accounts payable	17,000	17,000	51,000	1	0
Right-of-use assets obtained in exchange for lease obligation	0	0	2	9	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro